US Edition‘Ozempic face’ may be driving a cosmetic surgery boom
UNITED STATES, JUL 30 – The American Society of Plastic Surgeons reports 40% of GLP-1 users consider cosmetic surgery to counter facial volume loss caused by rapid weight loss from drugs like Ozempic.
- Cosmetic surgeons in the U.S. report an 8% rise in facelifts between 2022 and 2023, linked to side effects from weight loss drugs like Ozempic.
- The spike follows increased use of GLP-1 drugs, especially semaglutide-based medications originally approved for diabetes in 2017 but now widely prescribed for weight loss.
- Patients, especially older adults, experience volume loss in their faces, often called 'Ozempic face,' involving sagging skin and muscle loss after rapid weight loss.
- About 1 in 8 U.S. adults have used GLP-1 drugs with nearly 40% using them solely to lose weight, and 2 in 5 patients considering or undergoing cosmetic surgery due to these effects.
- Surgeons emphasize medications as a temporary aid and highlight the need for surgical and lifestyle interventions to manage weight-loss-related aesthetic changes.
Insights by Ground AI
Does this summary seem wrong?
26 Articles
26 Articles
Local 3 NewsReposted by 
KVIA
KVIAAbout two years ago, celebrity cosmetic dermatologist Dr. Paul Jarrod Frank noticed a new type of patient arriving at his New York City practice. Amid the explosive increase in hair loss in the United States…
About two years ago, celebrity cosmetic dermatologist Dr. Paul Jarrod Frank noticed the arrival of a new type of patient in his New York office. Amid the explosive increase in people in the United States who lost weight with drugs like Ozempic, he observed a “drastic increase” of clients experiencing side effects ...
Coverage Details
Total News Sources26
Leaning Left1Leaning Right0Center22Last UpdatedBias Distribution96% Center
Bias Distribution
- 96% of the sources are Center
96% Center
C 96%
Factuality
To view factuality data please Upgrade to Premium
